PTC Therapeutics, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy.
